Bouhajja Bechir, Souissi Sami, Ghazali Hanene, Yahmadi Anouar, Mougaida Moez, Laamouri Noura, Sellami Ali, Chkir Mahbouba
Tunis Med. 2014 Feb;92(2):147-53.
Fibrinolysis during ST elevation myocardial infarction (STEMI) is feasible in the emergency departments (ED), and this reduces the delay from first medical contact to coronary reperfusion. The aim of the study is to: 1) Evaluate fibrinolysis with streptokinase (SK) in STEMI admitted to the ED. 2) identify clinical criteria predictive of fibrinolysis success.
prospective study (July 2008-March 2012). Inclusion of STEMI thrombolysed by SK. Fibrinolysis success was defined according to clinical and Electrocardiogram criteria. Multivariate study is used to identify the factors associated with thrombolysis success.
Out of the 329 STEMI enrolled during the study period, 224 (68%) were thrombolysed. Mean age = 57 ± 11 years (20-86 years) sex ratio = 6. The average time chest pain - emergency admission was 195 ± 177 min (15 min to 12 hours). The 2/3 of patients had consulted during the first 3 hours. The average success rate of thrombolysis was 59% and reached 83% the first hour, 66% the second hour and 58.7% the third hour. In multivariate analysis, the three independent predictors factors of a fibrinolysis success were: active smoking, current treatment with beta blockers and the delay from onset chest pain to the ED visit less than 180 min. Conversely, diabetes was associated with fibrinolysis failure. Fibrinolysis got complicated by two intracerebral hemorrhages. Three patients had died in the ED.
Two thirds of patients with STEMI have consulted 3 h after onset of chest pain. Fibrinolysis with streptokinase was effective in 59% of cases.
ST段抬高型心肌梗死(STEMI)患者在急诊科进行纤溶治疗是可行的,这可减少从首次医疗接触到冠状动脉再灌注的延迟。本研究的目的是:1)评估在急诊科收治的STEMI患者中使用链激酶(SK)进行纤溶治疗的效果。2)确定预测纤溶治疗成功的临床标准。
前瞻性研究(2008年7月至2012年3月)。纳入接受SK溶栓治疗的STEMI患者。根据临床和心电图标准定义纤溶治疗成功。采用多变量研究确定与溶栓成功相关的因素。
在研究期间纳入的329例STEMI患者中,224例(68%)接受了溶栓治疗。平均年龄=57±11岁(20 - 86岁),性别比=6。胸痛至急诊入院的平均时间为195±177分钟(15分钟至12小时)。三分之二的患者在最初3小时内就诊。溶栓的平均成功率为59%,第1小时达到83%,第2小时为66%,第3小时为58.7%。多变量分析中,纤溶治疗成功的三个独立预测因素为:当前吸烟、正在接受β受体阻滞剂治疗以及胸痛发作至急诊就诊的延迟时间小于180分钟。相反,糖尿病与纤溶治疗失败相关。纤溶治疗并发2例脑出血。三名患者在急诊科死亡。
三分之二的STEMI患者在胸痛发作后3小时内就诊。链激酶纤溶治疗在59%的病例中有效。